Key Highlights

● Faeth plunged on November 9 after early Phase 2 results disappointed.

● The stock lost roughly half its value at one point.

● The regimen shrank tumors in about one in three assessable patients.

● The stock had run up heading into the data.

A run-up, then a reversal

Faeth Therapeutics (NASDAQ:FTH) plunged on Monday, November 9, 2026, after early Phase 2 results from its PIKTOR program in advanced endometrial cancer disappointed investors. The stock lost roughly half its value at one point in the morning, according to news reports, and was still down by close to half in an early-afternoon reading.

According to market coverage, the regimen shrank tumors in about one in three assessable patients. That result fell below investor hopes after the stock had run up heading into the data.

Why solid data can still sink a stock

In oncology, shrinking tumors in a third of patients with advanced disease can be clinically meaningful. But stock prices reflect expectations, not just results. When shares climb ahead of a readout, investors are effectively betting on a strong outcome. If the data come in merely solid, or below what the most optimistic holders anticipated, the stock can fall sharply as those bets unwind.

This pattern, which traders often sum up as buying the rumor and selling the news, is common in small-cap biotech, where a single dataset can drive much of a company's value. Early-stage results also tend to involve relatively small groups of patients, which makes them harder to interpret. A handful of responses in either direction can change the headline figure, so investors often wait for larger studies before forming firm conclusions, but the stock market tends to react immediately.

About Faeth and endometrial cancer

Faeth Therapeutics, which some data providers still list under the name of its predecessor company, Sensei Biotherapeutics, is a clinical-stage biotech working on cancer treatments. Its PIKTOR program is being studied in advanced endometrial cancer, which starts in the lining of the uterus. Endometrial cancer is among the more common gynecologic cancers, and patients with advanced or recurrent disease often have limited treatment options, which is why new approaches draw interest from patients, doctors and investors alike.

A rough day for several biotechs

Faeth was among the session's biggest decliners. Zura Bio (NASDAQ:ZURA) collapsed after its lead drug failed a mid-stage study in the skin disease hidradenitis suppurativa, according to market reports, while Janux Therapeutics (NASDAQ:JANX) tumbled after early data disappointed investors, according to market data. Ionis Pharmaceuticals (NASDAQ:IONS) and ImmunityBio (NASDAQ:IBRX) also fell sharply.

The overall market went the other direction. The Nasdaq Composite surged 673.71 points to 25,253.14, its best day since July 30, and the Russell 2000 rallied 86.71 points to 2,840.81. All 11 S&P 500 sectors rose as oil slid on hopes for a US-Iran peace deal and chip stocks rebounded.

More Data Needed to Rebuild Hopes

The full dataset will be important. Investors will look for details on how long tumor responses last, how many patients saw their disease stabilize, and the safety profile of the regimen. Those factors can matter as much as the headline response rate in judging whether a cancer treatment is worth advancing.

Faeth's plans for the next stage of development, and how it will fund them, will also be closely watched. Small biotechs often need to raise money after setbacks, which can affect existing shareholders. On the macro front, Tuesday's October Consumer Price Index is the last Inflation report before the Federal Reserve's December 8-9 meeting.